Participated · Series A · Jun 2026

Scaled Cognition develops enterprise-focused AI models and tooling, with a flagship model called APT that aims to deliver human-like conversational fluency while reducing hallucinations. Its platform encompasses models, agent tools, simulation and evaluation frameworks, and real-time agent monitoring to support AI agents that take actions in high-stakes contexts. The company is co-founded by Dan Klein (CTO) and Dan Roth (CEO) and is based in Mountain View, CA. Financially, it recently raised $100M in a Series A led by Khosla Ventures with participation from Genesys. The firm plans to use the new capital to expand operations and accelerate development efforts. The article does not report revenue, user counts, or a valuation.

Participated · Series C · Mar 2022

Cresta offers an end-to-end generative AI platform that provides real-time agent assistance, AI-driven quality management, coaching, and human-like virtual agents for contact centers. The platform surfaces real-time insights and behavioral best practices to scale winning behaviors across human agents while automating repetitive tasks with virtual agents. Cresta serves large customers including Intuit, Verizon, Brinks Home, Cox Communications, Hilton, and Carmax. The company says it nearly quadrupled annual recurring revenue (ARR) and nearly doubled its customer base in the last two years. Cresta plans to double down on its existing product suite, scale go-to-market efforts, and rapidly develop the next generation of virtual agents. To support R&D and scale, Cresta is opening two new engineering hubs in Romania and India in addition to existing offices in Palo Alto, San Francisco, New York, Berlin, and Toronto. Cresta builds a real-time intelligence platform for contact centers that turns real-time intelligence into real-time action. The company offers three solutions—Cresta for Agents, Cresta for Managers, and Cresta for Business—designed to improve agent performance and business outcomes. Cresta powers customer experiences for customers including CarMax, Blue Nile, Earthlink, Intuit, and Porsche. Led by CEO and co‑founder Zayd Enam and based in San Francisco, the company recently expanded its engineering and product leadership by hiring Ping Wu, co‑founder of Google Contact Center AI, as VP of Engineering and Product. The business closed a significant financing round in 2022, positioning it for further product and go‑to‑market growth. Cresta develops the Cresta Expertise Engine, an AI platform that offers real-time mentoring and feedback across customer communications to improve productivity for sales and service teams. The company also announced Cresta for Voice, a phone-based solution that provides real-time agent assistance and coaching, call transcription, dynamic reminders for key behaviors, and access to knowledge-base answers. Customers named in the article include Intuit, Porsche and Cox Communications. Led by co-founder and CEO Zayd Enam, Cresta plans to use new funding to support growth and further develop its Expertise Engine. The company highlights measurable business outcomes delivered within weeks for phone-based teams. The board includes former AT&T CEO John Donovan and co-founder Sebastian Thrun. Cresta builds AI-driven software that provides live suggestions and coaching to human contact-center agents and salespeople, using natural language processing to surface actions that worked in past successful interactions. The product focuses on improving conversation outcomes rather than fully automating exchanges, offering in-call guidance and training to reduce the impact of high turnover and limited employee experience. Cresta emphasizes close customer engagement, with its team living onsite with customers to tailor deployments. The company launched from stealth and has a roughly 30-person team led by CEO Zayd Enam; Sebastian Thrun is board chairman and listed as a co-founder. Cresta positions itself against established AI contact-center products from Salesforce, Google and Twilio while arguing its customer-obsessed team gives it an edge. Financially, the company has raised institutional backing to support growth, most recently from Greylock and Andreessen Horowitz.

Led · Series B · Feb 2021

Limitless Technology offers an AI-driven GigCX SaaS platform that combines crowdsourcing and machine intelligence to deliver on-demand customer support. The platform sources customer support agents on a cost-per-serve basis and blends gig experts with contact-centre agents to scale during peak demand. Limitless says its solution addresses rising support costs, attrition, variability in demand, and the need for workforce diversity, and it works with clients including Microsoft, Unilever, Sage, eBay, and L’Oreal. The company has formed a partnership and integration with Genesys Cloud to provide seamless routing and 24/7 responsiveness. Limitless plans to establish a new US-based headquarters and focus product development on routing, automation, and AI that augments human agents. Financially, the company announced a $10M Series B following a nearly $7M Series A in 2019.

Participated · Series B · Feb 2021

Limitless operates a GigCX platform, SmartCrowd™, that combines crowdsourcing and AI to enable brands to engage expert customers as on-demand support agents. The platform offers a task-based, flexible model that helps businesses scale resources during busy periods and deliver faster, personalised responses around the clock. Customers using the platform include Microsoft, Unilever, Sage, eBay and L’Oreal. The company is led by CEO Roger Beadle and COO Megan Neale. Limitless has a technology partnership with Genesys to integrate Genesys Cloud with its GigCX platform, allowing product and technical experts to provide gig support through the combined solution. The company plans to use new funding to expand in the US, establish a US-based headquarters, and focus product development on routing, automation and AI. Limitless provides a SaaS platform, SmartCrowd™, that uses AI and crowdsourcing to turn loyal customers into paid ‘Customer Experts’ who deliver on-demand support. Its SmartCrowd suite comprises four solutions: CrowdService®, CrowdCoach™, CrowdAdvise™ and CrowdFeedback™. The platform is used by over 100 brands, including Microsoft, Unilever, Vodafone, Daily Mail Group, National Express, Wargaming, Northumbrian Water and Amazon. Customers adopting SmartCrowd report up to 50% cost reductions and access to 24/7, multilingual support via a flexible talent pool. Limitless plans to further develop SmartCrowd and its machine-learning SmartAI™ capabilities, and to expand sales and operations across Europe, North America, Asia and India.

Participated · Series B · Sep 2020

Inversago Pharma is a clinical-stage biotech in Montreal focused on developing first-in-class, peripherally-acting CB1 inverse agonists. Its lead program, INV-202, is being advanced for Diabetic Kidney Disease (DKD) and is slated to enter a Phase 2 clinical trial in Q4 2022. The company announced FDA IND clearance for INV-202 and expects Phase 1b topline results in subjects with metabolic syndrome. Proceeds from the Series C will also accelerate multiple preclinical programs across its pipeline. Inversago aims to establish leadership in the field of CB1 blockade and to develop therapies for cardiometabolic, fibrotic, and other metabolic conditions. The company is privately owned and targets indications including DKD, Type 1 and Type 2 Diabetes, NASH, complications of obesity, hypertriglyceridemia, and progressive-fibrosis interstitial lung diseases. Inversago Pharma is a preclinical-stage biotech focused on first-in-class, peripherally-acting CB1 inverse agonists. Its lead candidate is INV-101 and the company plans to use recent proceeds to advance INV-101 to clinical proof-of-concept while progressing research on other selected compounds. Inversago targets metabolic and fibrotic conditions including Prader-Willi syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes and diabetic nephropathy. The company’s approach is designed to inhibit peripheral CB1 signaling—thought to be activated in many of these diseases—while avoiding the CNS liabilities associated with central CB1 blockade. Clinical and scientific data cited by the company support CB1 inhibition as an effective therapeutic strategy in several diseases, and Inversago emphasizes a safer therapeutic window through peripheral-only action. Following the financing the company expanded its board to help transition from preclinical work toward first-in-human trials. Inversago Pharma is a Montreal-based, preclinical-stage company developing new generations of peripherally-restricted CB1 inverse agonists/antagonists for Prader-Willi Syndrome, type 1 diabetes, obesity and other metabolic disorders including NASH. Its core product is a CB1 receptor blocker designed to avoid the central nervous system adverse events that terminated earlier, centrally-acting CB1 programs. The company’s technology is based on work by CB1 expert George Kunos at the NIH/NIAAA and has shown in preclinical models that peripheral CB1 blockade can treat obesity, NASH, liver fibrosis and diabetes without the behavioral CNS effects of earlier compounds. Inversago intends to advance its peripherally-restricted CB1 program into clinical trials. The company launched operations to exploit the therapeutic potential of reinstated CB1 blockade across multiple metabolic indications. The announced Series A financing will support the company’s development plan and progression toward clinical development.